- Profit after tax
- Rs 184.9 mn
- EPS
- Rs 2.09 +15.5%
- EPS a year earlier
- Rs 1.81
Last close · 13 Nov 2026
Rs 135.26 ▼ 1.13 (-0.83%)
▼ 10.8% 1 year
- Market cap
- —
- P/E
- —
- FY2026
- P/B
- —
- FY2026
- Dividend yield
- —
- FY2026
- ROE
- 12.7%
- FY2026
- Sector 21.7% · lower
- EPS
- —
- FY2026
- Book value / share
- —
- FY2026
Price performance
BFBIO returns
Close Rs 135.26
13 Nov 2026
| Period | Return | Rs | vs KSE-100 |
|---|---|---|---|
| MTD Month to date | +7.1% +0.2 pts vs KSE | +8.99 | +0.2 pts KSE +6.9% |
| 3M 3 months | +0.0% +1.3 pts vs KSE | +0.01 | +1.3 pts KSE −1.2% |
| 6M 6 months | −0.5% −6.8 pts vs KSE | −0.72 | −6.8 pts KSE +6.2% |
| YTD Year to date | −3.7% −5.9 pts vs KSE | −5.26 | −5.9 pts KSE +2.2% |
| FYTD Fiscal year to date | −5.3% −4.0 pts vs KSE | −7.62 | −4.0 pts KSE −1.4% |
| 1Y 1 year | −10.8% −21.6 pts vs KSE | −16.45 | −21.6 pts KSE +10.7% |
Price return from the last close before each period; the fiscal year ends 30 June. Dividends are not included.
BF Biosciences Limited in brief
Return on equity was 12.7%.
Scorecard vs Pharmaceuticals
14 companies- Growth
- No figure
- —
- Profitability
- No figure
- —
- Financial health
- No figure
- —
- Valuation
- No figure
- —
- Dividends
- No figure
- —
Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.
Corporate
BFBIO announcements & payouts
- Profit after tax
- Rs 632.1 mn
- EPS
- Rs 7.16 +29.7%
- EPS a year earlier
- Rs 5.52
Book closure 21 Oct – 28 Oct 2026
- Profit after tax
- Rs 464.9 mn
- EPS
- Rs 5.26 +28.9%
- EPS a year earlier
- Rs 4.08
- Profit after tax
- Rs 347.3 mn
- EPS
- Rs 3.93 +47.7%
- EPS a year earlier
- Rs 2.66
Financial highlights
BFBIO financial results
| Rs mn | FY2026 Jul 2025 – Jun 2026 | FY2025 Jul 2024 – Jun 2025 | FY2024 Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 | FY2021 Jul 2020 – Jun 2021 | FY2020 Jul 2019 – Jun 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | 5,837.5 | 3,658.7 | 1,809.5 | 1,520.7 | 1,754.8 | 628.3 |
| Gross profit | — | 2,286.1 | 1,532.0 | 449.0 | 457.8 | 796.5 | 86.5 |
| Operating profit | 1,089.4 | 735.4 | 711.7 | 270.3 | 246.9 | 610.2 | 21.2 |
| Profit after tax | — | 447.1 | 385.4 | 149.1 | 307.0 | 608.0 | 47.1 |
| Profit attributable to shareholders | — | 447.1 | 385.4 | 149.1 | 307.0 | 608.0 | 47.1 |
| EPS – basic (Rs) Rs | — | 5.52 | 4.36 | 1.69 | 3.48 | 6.88 | 0.53 |
| Dividend per share (Rs) Rs | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | — | 8,158.5 | 5,860.0 | 5,666.8 | 4,435.1 | 2,994.8 | 1,047.7 |
| Total equity | — | 4,662.0 | 2,359.6 | 1,974.2 | 1,825.2 | 1,466.6 | 782.4 |
| Total debt | — | 1,724.8 | 2,212.3 | 2,602.7 | 1,744.1 | 889.4 | 6.4 |
| Net cash from operating activities | — | 282.6 | 519.5 | (232.9) | 292.0 | 583.7 | (12.0) |
| Capital expenditure | — | (329.5) | (143.1) | (1,970.0) | (1,130.2) | (941.1) | (22.2) |
| Free cash flow (operating cash flow − capex) | — | (46.9) | 376.4 | (2,203.0) | (838.1) | (357.4) | (34.2) |
| Rs bn | TTM to Jun 2026 | Q4 FY2026 Apr – Jun 2026 | Q3 FY2026 Jan – Mar 2026 | Q2 FY2026 Oct – Dec 2025 | Q1 FY2026 Jul – Sep 2025 | Q4 FY2025 Apr – Jun 2025 | Q3 FY2025 Jan – Mar 2025 | Q2 FY2025 Oct – Dec 2024 | Q1 FY2025 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 2.1 | 2.7 | 2.4 | 1.6 | 1.5 | 1.3 | 1.4 |
| Gross profit | — | — | 1.0 | 1.2 | 1.0 | 0.6 | 0.5 | 0.6 | 0.6 |
| Operating profit | — | — | 0.2 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| Profit after tax | — | — | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Profit attributable to shareholders | — | — | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| EPS – basic (Rs) Rs | — | — | 1.33 | 2.13 | 1.81 | 1.44 | 1.59 | 1.37 | 1.30 |
| Dividend per share (Rs) Rs | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | — | — | 9.2 | 10.0 | 8.7 | 8.2 | 8.2 | 8.4 | 8.2 |
| Total equity | — | — | 5.1 | 5.0 | 4.8 | 4.7 | 4.5 | 4.4 | 2.5 |
| Total debt | — | — | 1.7 | 1.6 | 1.8 | 1.7 | 1.9 | 2.1 | 2.3 |
| Net cash from operating activities | — | — | (0.8) | 0.6 | 0.0 | 0.5 | (0.4) | 0.2 | 0.0 |
| Capital expenditure | — | — | (0.1) | (0.2) | (0.1) | (0.1) | (0.0) | (0.1) | (0.1) |
| Free cash flow (operating cash flow − capex) | — | — | (1.0) | 0.4 | (0.0) | 0.4 | (0.4) | 0.1 | (0.1) |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.
BFBIO charts
Valuation
BFBIO valuation at today's price
- Price to earnings (P/E)
- —
- EPS — (FY2026)
- Price to book (P/B)
- —
- Book value — (FY2026)
- Dividend yield
- —
- DPS — (FY2026)
- Earnings yield
- —
- EPS ÷ price
At the closing price of Rs 135.26 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.
Sector peers
BFBIO vs Pharmaceuticals companies
| Company | Market cap | P/E | P/B | Yield | ROE | 3-yr growth |
|---|---|---|---|---|---|---|
| BFBIO | — | — | — | — | 12.7% | — |
| GLAXO | Rs 107.1 bn | 10.3× | 3.11× | 5.1% | 32.4% | 16.3% |
| ABOT | Rs 97.9 bn | 11.4× | 3.05× | 4.0% | 28.8% | 15.2% |
| HALEON | Rs 81.6 bn | 12.4× | 5.02× | 4.3% | 47.6% | 16.2% |
| HINOON | Rs 50.8 bn | 12.8× | 3.95× | 5.2% | 32.3% | 20.5% |
| AGP | Rs 43.8 bn | 11.7× | 2.92× | 5.1% | 25.9% | 26.0% |
| HPL | Rs 38.5 bn | 10.3× | 4.50× | 6.0% | 38.6% | 18.6% |
| FEROZ | Rs 15.8 bn | 16.1× | 1.19× | 1.5% | 7.6% | 27.9% |
| CPHL | Rs 14.5 bn | 18.3× | 1.34× | 0.0% | 7.3% | 4.3% |
Analyses & signals 0
Win rate — · 0 closed signals · average return —
No analyses published for BFBIO yet.
BFBIO: frequently asked questions
How has BFBIO's share price performed?
BFBIO's share price is down 3.7% year to date (KSE-100: +2.2%) and down 10.8% over one year (KSE-100: +10.7%), as of 13 Nov 2026. These are price returns; dividends are not included.
Information only, not investment advice.